Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Downgrades Vyant Bio to Neutral

HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.

byBenzinga Newsdesk

February 3, 2023

1 minute read

HC Wainwright & Co. analyst Edward White downgrades Vyant Bio (NASDAQ:VYNT) from Buy to Neutral.

Recap: Mersana Therapeutics Q4 Earnings

By Benzinga Insights

Today, 7:39 PM

Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

MRSN

Analyst Ratings

Analyst Expectations for Clearside Biomedical’s Future

By Benzinga Insights

Today, 7:39 PM

Analysts have provided the following ratings for Clearside Biomedical (NASDAQ:CLSD) within the last quarter: Bullish Somewhat Bullish Indifferent…

CLSD

Deutsche Bank Maintains Hold on Texas Instruments, Lowers Price Target to $170

By Benzinga Newsdesk

Today, 7:39 PM

Deutsche Bank analyst Ross Seymore maintains Texas Instruments (NASDAQ:TXN) with a Hold and lowers the price target from $185 to $170.

TXN

4 Stocks Insiders Are Selling

By Lisa Levin

Today, 7:39 PM

When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.

GPI

HC Wainwright & Co. Downgrades Vyant Bio to Neutral

Related Posts

Recap: Mersana Therapeutics Q4 Earnings

Analyst Expectations for Clearside Biomedical’s Future

Deutsche Bank Maintains Hold on Texas Instruments, Lowers Price Target to $170

4 Stocks Insiders Are Selling